Jeanne Calment was 85 years old when Vincent van Gogh died.

She had met him as a teenager in her father’s art supply shop in Arles, France — a scruffy, intense man who came in to buy canvas. She described him, decades later, as dirty, badly dressed, and disagreeable. She outlived him by 107 years. She outlived the Wright brothers’ first flight, two world wars, the moon landing, the fall of the Berlin Wall, and the invention of the internet. She was born three years before the light bulb was patented and died six years before the iPhone was released.

Jeanne Calment lived to 122 years and 164 days — the longest verified human lifespan in recorded history — and she remains, nearly three decades after her death, the only person ever confirmed to have lived past 120. Not for lack of trying, and not for lack of medicine. Simply because arriving at that age appears to be extraordinarily, vanishingly rare — even as more people than ever before are living into their nineties and beyond.

The question of why is one of the more fascinating and more consequential questions in contemporary science. Not just academically but urgently: we are an ageing species in an ageing world, and understanding the mechanisms that govern how long human beings can live — and whether those mechanisms can be influenced — has implications that extend from individual health decisions to global economics to the deepest questions of what it means to be human.

This article is an attempt to address that question as honestly and as interestingly as the current science allows.

Why We Age At All — The Question Underneath the Question

Before getting to limits, it helps to understand ageing itself, because the question of how long humans can live cannot be fully separated from the question of why our bodies deteriorate in the first place.

The simple answer — that we wear out over time, like machines — turns out to be inadequate. Organisms do not age at uniform rates. Mice age and die within two to three years. Bowhead whales live for more than two centuries. The naked mole rat, a small rodent that lives underground in East Africa, defies essentially every expectation for a creature of its size — it lives for up to thirty years, rarely develops cancer, and shows almost no increase in mortality risk with age, a property so unusual it has attracted significant scientific attention. Greenland sharks are estimated to live for four hundred years or more.

The variation in ageing rates across species tells us something important: ageing is not simply the inevitable consequence of time passing. It is a biological process — one that evolution has shaped differently in different lineages, presumably in response to different environmental pressures and different trade-offs between survival, reproduction, and cellular maintenance.

The leading evolutionary theory of ageing, developed by biologists including Peter Medawar and George Williams in the mid-twentieth century, suggests that natural selection has limited power to prevent ageing and age-related disease because most of these problems occur after the peak reproductive period. Genes that cause damage in later life are largely invisible to selection if they have already served their purpose by promoting survival and reproduction in early life. The accumulation of such genes — combined with declining investment in cellular maintenance as the reproductive payoff of that investment diminishes with age — produces the progressive deterioration we recognise as ageing.

This framing has a counterintuitive implication. Ageing, in this view, is not programmed in any simple sense. It is more accurate to say that immortality is not selected for. The body does not actively plan its own deterioration — it simply invests less and less in the machinery that would prevent it. Understanding which machinery matters most, and whether it can be reinforced, is the central project of modern longevity research.

The Cellular Clock — The Hayflick Limit and What It Actually Means

In 1961, a biologist named Leonard Hayflick made a discovery that fundamentally changed how scientists thought about ageing at the cellular level.

Working with human foetal lung cells in culture, Hayflick noticed something that contradicted the prevailing assumption that cells could divide indefinitely under the right conditions. The cells divided enthusiastically for a time — approximately fifty times — and then, without any apparent external cause, they stopped. They entered a state of permanent non-division that he called cellular senescence. They were still alive, but they had irrevocably lost the ability to replicate.

This discovery became known as the Hayflick Limit — the observation that normal human cells have a finite replicative capacity, somewhere between forty and sixty divisions depending on the cell type. And it raised an immediate question: what is the cells counting with?

The answer, which took another two decades of research to work out fully, turned out to be telomeres — protective caps at the ends of chromosomes, analogous to the plastic tips on shoelaces, that shorten slightly with each cell division. When telomeres become critically short, the cell detects this as DNA damage and enters senescence rather than risk the genomic instability that would result from continuing to divide with inadequately protected chromosome ends.

The theoretical connection between the Hayflick Limit and the maximum human lifespan is appealing in its simplicity: if cells can only divide a certain number of times, and each division takes a certain amount of time, then there is a calculable maximum lifespan implied by the replicative limit. Working backward from fifty divisions with typical cell cycle times, the implied ceiling aligns somewhat with the 120-year range represented by the oldest verified human ages.

But the picture is considerably more complicated than this simple calculation suggests. Not all cells divide at the same rate. Many cells in the adult body — neurons, cardiac muscle cells — divide very rarely or not at all after early development. And the relationship between telomere shortening, cellular senescence, and whole-organism ageing involves layers of complexity that researchers are still working to understand. The Hayflick Limit is an important piece of the puzzle. It is not the whole picture.

Senescent Cells — The Zombie Problem

One of the more striking developments in recent ageing research is the growing understanding of what senescent cells actually do once they have stopped dividing — and why that matters for the ageing of the whole organism.

Senescent cells do not simply become inert. They enter a state that researchers have characterised as the senescence-associated secretory phenotype — a condition in which the cell, unable to divide, begins secreting a cocktail of inflammatory signalling molecules into the surrounding tissue. The apparent purpose of this signalling is to recruit immune cells that would normally clear the senescent cell — a kind of distress signal. In young organisms with robust immune function, this works reasonably well. Senescent cells are flagged and removed relatively efficiently.

In older organisms, two things go wrong. The immune system becomes less effective at clearing senescent cells, so they accumulate. And the inflammatory signalling those accumulated cells produce — called inflammaging in the research literature — creates a chronic low-grade inflammatory state in surrounding tissues that contributes to essentially every major age-related disease: cardiovascular disease, type 2 diabetes, neurodegeneration, cancer, osteoporosis.

This has made senescent cell clearance one of the more active areas in longevity research. Drugs called senolytics, which selectively eliminate senescent cells, have shown remarkable effects in animal models — restoring some measures of physical function, reducing inflammatory markers, and in some cases extending healthy lifespan. Human clinical trials are underway. The results so far are intriguing but preliminary, and the gap between promising animal data and proven human benefit in this area, as in many areas of ageing research, remains significant.

The Genetic Architecture of Longevity — What Your DNA Actually Determines

The question of how much genetics determines individual lifespan is one that has attracted substantial research attention and produced a somewhat surprising answer.

Studies of twins — which allow researchers to separate genetic from environmental influences by comparing outcomes in genetically identical versus fraternal twins — consistently find that genetic factors account for approximately twenty to thirty percent of the variation in lifespan between individuals. This is a meaningful contribution but a more modest one than many people assume. It means that the majority of variation in how long people live is attributable to non-genetic factors — lifestyle, environment, access to healthcare, and the various accidents of circumstance that shape the trajectory of a life.

Within the genetic contribution, several specific genes and genetic variants have been associated with exceptional longevity across multiple studies. The FOXO3 gene is perhaps the most consistently replicated finding — specific variants of this gene, involved in regulating cellular stress responses and metabolism, appear in higher frequency among centenarians across multiple different populations and have been connected to improved cellular maintenance and more effective handling of oxidative stress.

The APOE gene, associated with cholesterol metabolism and risk for Alzheimer’s disease, shows the reverse pattern — the APOE4 variant, which increases Alzheimer’s risk, is significantly underrepresented among people who live into their late nineties and beyond. Surviving to exceptional old age appears to require, among other things, avoiding the genetic variants most strongly associated with the diseases that typically kill people in their seventies and eighties.

The broader genetic picture of longevity that is emerging from large-scale genomic studies is one of many small effects rather than a few large ones. There does not appear to be a single longevity gene that dramatically extends lifespan when present. Instead, exceptional longevity appears to reflect the cumulative benefit of many small genetic advantages — in cellular maintenance, metabolic regulation, immune function, and disease resistance — combined with lifestyle and environmental factors that allow those genetic advantages to express themselves.

The Factors Within Your Control — What the Evidence Actually Shows

Given that genetics accounts for only about a quarter of lifespan variation, the factors under individual influence matter enormously. The research on what specifically makes the largest difference is extensive enough to allow some reasonably confident conclusions.

Diet — The Pattern Matters More Than Individual Foods

The most consistent finding from dietary research on longevity is that overall dietary patterns matter far more than any individual food or nutrient. The populations that have historically shown the highest rates of exceptional longevity — the so-called Blue Zones, including Sardinia in Italy, Okinawa in Japan, and the Nicoya Peninsula in Costa Rica — share broadly similar dietary characteristics despite significant differences in specific foods.

These characteristics include high consumption of vegetables, legumes, and whole grains that form the base of the diet. Moderate protein intake, predominantly from plant sources. Limited consumption of processed foods, added sugars, and refined carbohydrates. Moderate total caloric intake — not dramatic restriction, but an absence of the chronic caloric excess that characterises most modern Western diets. And in most of these populations, a culturally embedded practice of eating until approximately eighty percent full rather than to complete satiety — a practice that research on caloric restriction in animal models suggests may have genuine biological relevance to cellular maintenance processes.

The Mediterranean dietary pattern, which broadly shares these characteristics with the addition of olive oil as the primary fat source, has accumulated perhaps the strongest and most consistent evidence base for longevity-associated health outcomes of any dietary pattern studied in large human populations.

Physical Activity — The Anti-Ageing Intervention That Requires No Technology

The evidence for regular physical activity as a longevity-promoting behaviour is as strong as the evidence for anything in this field, and the mechanisms are well enough understood to be genuinely persuasive rather than merely correlational.

Exercise reduces chronic inflammation, improves cardiovascular function, promotes insulin sensitivity, supports healthy body composition, improves sleep quality, reduces risk of the majority of the diseases most likely to kill you prematurely, and — perhaps most directly relevant to the ageing question — has been shown to maintain telomere length in regular exercisers compared to sedentary individuals. The people who exercise consistently across their lives are not just healthier in the functional sense. They are, at the cellular level, biologically younger than their chronological age by measurable degrees.

The research on what type and quantity of exercise produces the most significant longevity benefits has become more nuanced as the evidence has accumulated. Moderate-intensity aerobic exercise — the kind that elevates heart rate without being maximally demanding — produces large benefits for cardiovascular and metabolic health. Resistance training, which is often underemphasised in longevity discussions focused on cardio, is increasingly recognised as critical for maintaining muscle mass and function across ageing — sarcopenia, the progressive loss of muscle with age, is now understood to be a major driver of functional decline and mortality risk in older adults. And high-intensity interval training appears to produce specific cellular benefits — including improvements in mitochondrial function — that steady-state exercise may not replicate as effectively.

The practical summary is that the optimal exercise approach for longevity involves all three categories rather than any one of them in isolation.

Social Connection — The Longevity Factor That Surprises People Most

Of all the factors associated with exceptional longevity across both the Blue Zone populations and the epidemiological research on ageing, the one that consistently surprises people most is the strength of the evidence for social connection.

The Roseto Effect — named for a Pennsylvania town of Italian immigrants studied in the 1960s — provided an early and striking demonstration of this. Roseto had dramatically lower rates of heart disease than surrounding towns despite sharing similar risk factors in diet, smoking, and genetics. The factor that distinguished Roseto was its unusually strong community cohesion — multigenerational households, strong social bonds, and a culture of mutual support that effectively buffered the physiological effects of individual stress. When those social structures began to erode in subsequent generations, Roseto’s heart disease rates converged with those of surrounding towns.

The research since Roseto has extensively documented the biological mechanisms through which social connection promotes health and longevity. Socially connected individuals show lower cortisol levels, lower inflammatory markers, better immune function, and lower rates of the mental health conditions — depression, anxiety, chronic stress — that themselves accelerate biological ageing. The Harvard Study of Adult Development, one of the longest-running studies of adult life ever conducted, found that the quality of close relationships was the single strongest predictor of health and happiness in later life — more predictive than cholesterol levels, income, social class, or IQ.

The effect of chronic loneliness on health, conversely, has been found to be comparable in magnitude to smoking fifteen cigarettes a day. This is not a soft finding. It is one of the more robust and replicated results in the epidemiology of ageing, and it has implications for how we think about the social dimensions of health that most medical and public health discourse still underweights.

Not Smoking — The Most Impactful Single Decision Available

The evidence on smoking and lifespan is so strong and so consistent that it barely requires elaboration. Smoking shortens life expectancy by approximately ten years on average. It is the single most avoidable cause of premature death in the world. The mechanisms are multiple — cardiovascular damage, carcinogenesis, chronic lung disease, accelerated cellular ageing — and the damage accumulates with every year of continued use. Cessation at any age produces measurable health benefits; cessation before forty reduces excess mortality risk by approximately ninety percent.

The Theoretical Ceiling — Is There a Maximum Human Lifespan?

This is the question that generates the most scientific controversy, and it is worth engaging with the disagreement honestly rather than presenting a false consensus.

A high-profile paper published in Nature in 2016 by researchers at the Albert Einstein College of Medicine argued, based on analysis of longevity data from multiple countries, that human lifespan had a natural ceiling of approximately 115 years, with rare outliers like Calment representing statistical extremes rather than evidence that the ceiling could be regularly exceeded. The paper attracted significant attention and immediate criticism from other researchers, who disputed the statistical approach and argued that the data did not support a fixed ceiling.

The disagreement illuminates a genuine difficulty in this research area: the number of people who have lived past 110 is small enough that drawing reliable conclusions from their ages about the shape of the underlying distribution is statistically challenging. The question of whether maximum lifespan is fixed at approximately 120, or whether it could be extended with sufficient biological understanding and intervention, is genuinely open.

What is clearer is the distinction between lifespan and healthspan — between how long people live and how long they live in good health. Even if the theoretical maximum human lifespan is fixed somewhere around 120 years, most people die considerably earlier than that, and the gap between average and maximum is filled mostly with years of manageable-to-significant disease burden. The more immediately relevant scientific question — and the one with the most direct implications for how most people should think about their health — is not whether it is possible to live to 125, but whether the healthy, functional years of life can be extended while the years of decline and disease burden are compressed into a shorter period at the very end.

This concept — often called compression of morbidity — is the more achievable and more personally relevant aspiration for most people. Living well until close to the end, rather than living long but spending many of those years in declining health.

The Future — Gene Editing, Regenerative Medicine, and Honest Uncertainty

The longevity science landscape in 2026 includes a number of developments that would have seemed like science fiction twenty years ago, and it is worth describing them honestly — which means neither dismissing them nor overselling them.

CRISPR and related gene editing technologies have created the ability to make precise modifications to the genome that were previously impossible. Applications to ageing research include the potential to correct or modify the expression of genes identified as longevity-associated or ageing-accelerating. Animal model results have been striking in some cases. Human applications face both significant technical challenges — delivering gene edits safely and specifically to the cells that matter, without off-target effects — and profound ethical questions about the appropriate scope of germline modification.

Senolytics, discussed earlier, are probably the most advanced of the interventions targeting specific ageing mechanisms in human populations. Clinical trials are examining their effects on conditions ranging from osteoporosis to pulmonary fibrosis to cardiovascular disease. The results so far suggest real effects in specific disease contexts. Whether they will translate into meaningful extensions of healthy lifespan in the general population remains to be established.

Rapamycin, a drug that acts on a cellular pathway called mTOR that is central to regulating cell growth and metabolism, has extended lifespan in mouse models even when started in middle age — a finding that generated significant excitement in the longevity research community. Human trials examining its effects on health and immune function in older adults are ongoing, and some physicians have begun prescribing it off-label for longevity purposes, though the evidence for this application in humans remains preliminary.

The honest position on all of these interventions is that they are genuinely promising, that the science underlying them is real and interesting, and that the distance between promising animal data and proven, safe, broadly available human longevity interventions remains large. The history of medicine is filled with interventions that looked transformative in animal models and disappointing in human trials. The history of ageing research specifically includes a long trail of compounds that extended lifespan in model organisms without translating to human benefit.

This does not mean the current wave of longevity research will follow that pattern. It means that appropriate scientific humility requires acknowledging the uncertainty while remaining genuinely interested in where the science goes.

What Jeanne Calment Actually Tells Us

I want to return to where we started, because I think Calment’s life offers something more useful than a record to wonder at.

She was asked, many times throughout her extraordinary old age, to what she attributed her longevity. She gave characteristically wry answers. She rode a bicycle until she was 100. She ate chocolate every day. She used olive oil on her skin. She took what came with equanimity — she described herself as never being bored, never being particularly worried, never letting the difficulties of life build into the kind of sustained distress that might have worn her out prematurely.

She also smoked, occasionally, until she was 117 — a fact that longevity researchers find instructive rather than reassuring, because it reflects the genuine role of genetic good fortune in exceptional survival. She had, almost certainly, the kind of genetic endowment that made her cells unusually resilient, her biology unusually capable of repair and maintenance, her body unusually resistant to the damage that typically shortens lives.

Most of us do not have that endowment. Which means the habits matter more for us than they mattered for her.

The research on what extends healthy human life converges, repeatedly and consistently, on the same unglamorous fundamentals: move your body regularly, eat in ways that support metabolic health without chronic excess, sleep adequately and consistently, maintain genuine relationships with people who matter to you, do not smoke, manage your stress at its source rather than simply coping with its symptoms, and engage with healthcare proactively rather than reactively.

These things will not make you 122. But they represent the most reliable path the science currently offers to the version of longevity that is within reach for most people — more years of genuine health, more years of full function, more years of being present and capable in the lives of the people you love.

That, in the end, is what most people actually want when they say they want to live longer. Not simply more time. More good time.

The science suggests that is more within our influence than most people realise.

If this piece gave you something to think about regarding your own health and longevity, share it with someone who is asking the same questions. And find more science and health content right here on DennisMaria.